Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291794 | 0.83 | POLB (0.52) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL16277225 | 0.80 | POLB (0.51) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL21696530 | 0.79 | CYP3A4 (0.59) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL21696581 | 0.79 | POLB (0.56) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL21696598 | 0.79 | POLB (0.56) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL21696748 | 0.79 | POLB (0.49) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL21696687 | 0.79 | VHL (0.59) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL15126261 | 0.79 | VHL (0.59) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL16277177 | 0.78 | POLB (0.51) | POLBMEN1KMT2AF2CYP3A4 | |
| SCHEMBL26787011 | 0.78 | POLB (0.57) | POLBMEN1KMT2AF2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | POLB 2671/4885MEN1 1693/4885KMT2A 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.